New cocktail approach targets hard-to-treat pancreatic cancer
NCT ID NCT04753879
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a low-dose combination of five chemotherapy drugs (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan) followed by two maintenance drugs (olaparib and pembrolizumab) in 38 people with untreated metastatic pancreatic cancer. The goal is to see if this approach can slow cancer growth and control the disease longer than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan, olaparib, pembrolizumab
What this could lead to
If successful, this could offer a new treatment option that delays cancer progression in people with metastatic pancreatic cancer.
What could go wrong
This is a small, early-phase trial (38 people) with no control group. The combination has significant side effects, and it may not improve survival or be better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States